ABIO — ARCA biopharma Income Statement
0.000.00%
- $60.35m
- $27.07m
- 45
- 31
- 91
- 56
Annual income statement for ARCA biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 5.81 | 9.77 | 19.3 | 10.6 | 7.3 |
Operating Profit | -5.81 | -9.77 | -19.3 | -10.6 | -7.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.65 | -9.75 | -19.3 | -9.93 | -5.34 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.48 | -9.74 | -19.3 | -9.93 | -5.34 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.48 | -9.74 | -19.3 | -9.93 | -5.34 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.48 | -9.74 | -19.3 | -9.93 | -5.34 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.15 | -2.07 | -1.39 | -0.689 | -0.37 |